Market cap
$642 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
6.7
P/B Ratio
1.8
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0.1
-
Book Value
$44.6
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
99,294,704
10 Years Aggregate
CFO
$15,178.86 Mln
EBITDA
$17,833.12 Mln
Net Profit
$8,654.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sinovac Biotech - ADR
| 0.0 | 0.0 | 0.0 | 0.0 | -- | 0.0 | 1.1 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
|---|---|
|
Sinovac Biotech - ADR
| 0.0 |
|
S&P Small-Cap 600
| 4.0 |
|
BSE Sensex
| 9.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Sinovac Biotech - ADR
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes... vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. Read more
-
Chairman, CEO, Pres, MD, GM & Sec.
Dr. Weidong Yin
-
Chairman, CEO, Pres, MD, GM & Sec.
Dr. Weidong Yin
-
Headquarters
Beijing
-
Website
FAQs for Sinovac Biotech - ADR
What is the current share price of Sinovac Biotech Ltd - ADR Today?
The share price of Sinovac Biotech Ltd - ADR is $6.47 (NASDAQ) as of 07-Jul-2026 16:00 EDT. Sinovac Biotech Ltd - ADR has given a return of 0% in the last 1 years.
What is the current PB & PE ratio of Sinovac Biotech Ltd - ADR?
The P/E ratio of Sinovac Biotech Ltd - ADR is 6.66 times as on 07-Jul-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-10.80 |
0.15 |
2024 |
7.09 |
0.08 |
2023 |
-6.45 |
0.07 |
2022 |
-- |
-- |
2021 |
0.09 |
0.08 |
What is the 52 Week High and Low of Sinovac Biotech Ltd - ADR?
The 52-week high and low of Sinovac Biotech Ltd - ADR are Rs 6.47 and Rs 6.47 as of 30-Aug-2026.
What is the market cap of Sinovac Biotech Ltd - ADR?
Sinovac Biotech Ltd - ADR has a market capitalisation of $ 642 Mln as on 07-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sinovac Biotech Ltd - ADR?
Before investing in Sinovac Biotech Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.